Anti-CD19 chimeric antigen receptor T cell therapy - Cellular Biomedicine Group

Drug Profile

Anti-CD19 chimeric antigen receptor T cell therapy - Cellular Biomedicine Group

Alternative Names: Anti-CD19 CART cell therapy - Cellular Biomedicine Group; Anti-CD19 CART cells; C-CAR011; CD19 specific CART cells

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chinese PLA General Hospital
  • Developer Cellular Biomedicine Group; Chinese PLA General Hospital
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Diffuse large B cell lymphoma; Follicular lymphoma; Leukaemia; Mantle-cell lymphoma
  • Phase I Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 01 Apr 2018 Peking Union Medical College Hospital, in collaboration with Cellular Biomedicine, plans a phase I trial for B-Cell Non-Hodgkin's lymphoma (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (NCT03483688)
  • 31 Oct 2017 Cellular Biomedicine and Peking University People's Hospital plan a clinical trial for Acute lymphoblastic leukaemia (In adolescents, In adults) in China (NCT03327285)
  • 03 Oct 2017 Cellular Biomedicine in collaboration with Tianjin Medical University Cancer Institute and Hospital plans a phase I trial for Non-Hodgkin's lymphoma (Second-line therapy or greater) (NCT03299738)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top